A Metabolomic-based Biomarker Discovery Study for Predicting Phototherapy Duration for Neonatal Hyperbilirubinemia

Overview

Journal Transl Pediatr

Publisher AME Publishing Company

Specialty Pediatrics

Date 2023 Jan 16

PMID 36643669

Authors

Danying Zhu

Mingjie Wang

Zhongxiao Zhang

Minghua Liu

Yiwen Liu

Weiling Wu

Dian Lu

Xiaoyun Wu

Wei Wu

Xingyun Wang

Affiliations

Soon will be listed here.

Abstract

Background: Phototherapy is a recommended method for the treatment of neonatal hyperbilirubinemia. However, biomarkers for predicting the more effective duration of phototherapy prior to treatment are lacking. Therefore, we aimed to determine novel predictors for the timing of phototherapy from the perspective of metabolomics.

Methods: A total of 12 newborns with neonatal hyperbilirubinemia were recruited on the day of admission. The infants were divided into a short-duration (<30 hours) phototherapy group and a long-duration (≥30 hours) phototherapy group based on the length of phototherapy treatment. Metabolites in serum samples were then explored using an untargeted metabolomics strategy.

Results: In total, 59 of 1,073 significantly different metabolites were identified between the short-duration and long-duration phototherapy groups, including 18 upregulated and 41 downregulated metabolites. The results of metabolomic analysis showed that the differentially expressed metabolites were enriched in glycerophospholipid metabolism, which is closely associated with the excretion of bilirubin. Moreover, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed that the metabolites were also enriched in alpha-Linolenic acid metabolism and fatty acid elongation. Spearman correlation hierarchical clustering analysis demonstrated that 9 metabolites were negatively correlated with the duration of phototherapy. Metabolites, especially phosphatidylethanolamine (PE) (22:1(13Z)/15:0), phosphatidylcholine (PC) (18:1(9Z)/18:1(9Z)), phosphatidylserine (PS) (22:0/15:0), 5,6-dihydrouridine, and PE (MonoMe(11,3)/MonoMe(13,5)), had better predictability for the duration of phototherapy [area under curve (AUC): 1; 95% confidence interval (CI): 1-1] than total serum total bilirubin and direct bilirubin (AUC: 0.806; 95% CI: 0.55-1), as revealed by receiver operating characteristic analysis.

Conclusions: Our research found that the differential metabolites were associated with the duration of neonatal jaundice and that glycerophospholipid metabolism might have played a role in this biological process. Moreover, metabolites such as PE (22:1(13Z)/15:0), PC (18:1(9Z)/18:1(9Z)), PS (22:0/15:0), 5,6-dihydrouridine, and PE (MonoMe(11,3)/MonoMe(13,5)) could be used as predictors for phototherapy duration in neonatal hyperbilirubinemia and assist with decision-making.

References

Meixiong J, Vasavda C, Green D, Zheng Q, Qi L, Kwatra S . Identification of a bilirubin receptor that may mediate a component of cholestatic itch. Elife. 2019; 8. PMC: 6368403. DOI: 10.7554/eLife.44116. View

Fujiwara R, Haag M, Schaeffeler E, Nies A, Zanger U, Schwab M . Systemic regulation of bilirubin homeostasis: Potential benefits of hyperbilirubinemia. Hepatology. 2017; 67(4):1609-1619. DOI: 10.1002/hep.29599. View

Moschos S, Sullivan R, Hwu W, Ramanathan R, Adjei A, Fong P . Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight. 2018; 3(4). PMC: 5916243. DOI: 10.1172/jci.insight.92352. View

Buitenwerf E, Dullaart R, Muller Kobold A, Links T, Sluiter W, Connelly M . Cholesterol delivery to the adrenal glands estimated by adrenal venous sampling: An in vivo model to determine the contribution of circulating lipoproteins to steroidogenesis in humans. J Clin Lipidol. 2017; 11(3):733-738. DOI: 10.1016/j.jacl.2017.03.018. View

Zeng S, Wang Z, Zhang P, Yin Z, Huang X, Tang X . Machine learning approach identifies meconium metabolites as potential biomarkers of neonatal hyperbilirubinemia. Comput Struct Biotechnol J. 2022; 20:1778-1784. PMC: 9027383. DOI: 10.1016/j.csbj.2022.03.039. View

Olusanya B, Kaplan M, Hansen T . Neonatal hyperbilirubinaemia: a global perspective. Lancet Child Adolesc Health. 2018; 2(8):610-620. DOI: 10.1016/S2352-4642(18)30139-1. View

Clos-Garcia M, Garcia K, Alonso C, Iruarrizaga-Lejarreta M, DAmato M, Crespo A . Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer. Cancers (Basel). 2020; 12(5). PMC: 7281174. DOI: 10.3390/cancers12051142. View

. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004; 114(1):297-316. DOI: 10.1542/peds.114.1.297. View

Khan N, Poduval T . Immunomodulatory and immunotoxic effects of bilirubin: molecular mechanisms. J Leukoc Biol. 2011; 90(5):997-1015. DOI: 10.1189/jlb.0211070. View

10.

Banoei M, Vogel H, Weljie A, Kumar A, Yende S, Angus D . Plasma metabolomics for the diagnosis and prognosis of H1N1 influenza pneumonia. Crit Care. 2017; 21(1):97. PMC: 5397800. DOI: 10.1186/s13054-017-1672-7. View

11.

Miles L, Miles M, Tang P, Horn P, Quinlan J, Wong B . Ubiquinol: a potential biomarker for tissue energy requirements and oxidative stress. Clin Chim Acta. 2005; 360(1-2):87-96. DOI: 10.1016/j.cccn.2005.04.009. View

12.

Zhou C, He M, Peng C, Yu J, Li Z, Zhou M . Pharmacokinetic and Lipidomic Assessment of the In Vivo Effects of Parishin A-Isorhynchophylline in Rat Migraine Models. J Anal Methods Chem. 2020; 2020:9101598. PMC: 7362284. DOI: 10.1155/2020/9101598. View

13.

DeBerardinis R, Keshari K . Metabolic analysis as a driver for discovery, diagnosis, and therapy. Cell. 2022; 185(15):2678-2689. PMC: 9469798. DOI: 10.1016/j.cell.2022.06.029. View

14.

Lamola A . A Pharmacologic View of Phototherapy. Clin Perinatol. 2016; 43(2):259-76. DOI: 10.1016/j.clp.2016.01.004. View

15.

Rinschen M, Ivanisevic J, Giera M, Siuzdak G . Identification of bioactive metabolites using activity metabolomics. Nat Rev Mol Cell Biol. 2019; 20(6):353-367. PMC: 6613555. DOI: 10.1038/s41580-019-0108-4. View

16.

Schwartz H, Haberman B, Ruddy R . Hyperbilirubinemia: current guidelines and emerging therapies. Pediatr Emerg Care. 2011; 27(9):884-9. DOI: 10.1097/PEC.0b013e31822c9b4c. View

17.

Xu Y, Jiang Y, Li Y . Pyrazinamide enhances lipid peroxidation and antioxidant levels to induce liver injury in rat models through PI3k/Akt inhibition. Toxicol Res (Camb). 2020; 9(3):149-157. PMC: 7329175. DOI: 10.1093/toxres/tfaa015. View

18.

Bugaiski-Shaked A, Shany E, Mesner O, Sergienko R, Wainstock T . Association Between Neonatal Phototherapy Exposure and Childhood Neoplasm. J Pediatr. 2022; 245:111-116. DOI: 10.1016/j.jpeds.2022.01.046. View

19.

Kelly S, Lanigan N, ONeill I, Bottacini F, Lugli G, Viappiani A . Bifidobacterial biofilm formation is a multifactorial adaptive phenomenon in response to bile exposure. Sci Rep. 2020; 10(1):11598. PMC: 7360559. DOI: 10.1038/s41598-020-68179-9. View

20.

Berman M, Carey M . Metastable and equilibrium phase diagrams of unconjugated bilirubin IXα as functions of pH in model bile systems: Implications for pigment gallstone formation. Am J Physiol Gastrointest Liver Physiol. 2014; 308(1):G42-55. PMC: 4281687. DOI: 10.1152/ajpgi.00277.2014. View